The Centers for Medicare & Medicaid Services (CMS) has said it will announce the next 15 drugs in scope for the second round ...

GSK Plc’s experimental drug helped prevent serious asthma attacks in two late-stage studies, easing the path forward for a ...

GSK’s GSK phase III study evaluating its blockbuster drug Nucala (mepolizumab), an anti-IL5 biologic, for treating chronic ...

British drugmaker GSK (GSK.L), opens new tab said on Wednesday it had agreed to settle two lawsuits in California that claimed its discontinued heartburn drug Zantac caused cancer. GSK does not ...

Meanwhile, the time has come to turn to our ever-growing to-do list. Sound familiar? So here are some items of interest. Have a great day, everyone. … Hims & Hers Health plans to sell compounded ...

Early data from GSK Plc and iTeos Therapeutics’ mid-stage trial of a lung cancer medicine looks set to renew cautious ...

GSK is continuing to tout depemokimab as one of its 12 potential blockbuster launches of the coming years, with the asthma drug expected to generate peak-year sales of 3 billion pounds sterling ($ ...

Specifically, on the key price-to-earnings ratio (P/E) measurement of relative stock valuation, it trades at just 16.7. This is at the bottom of the list of its peers ... is litigation over GSK’s ...

British drugmaker GSK said on Wednesday it had agreed to settle two lawsuits in California that claimed its discontinued heartburn drug Zantac caused cancer. GSK does not admit to any liability in ...